Skip to main content
36 search results for:

Tirzepatide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 03-07-2023 | Type 2 diabetes | News | Article

    ‘Substantial’ bodyweight reductions with tirzepatide in people with type 2 diabetes and obesity

    SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes.

  2. 26-07-2022 | Tirzepatide | News | Article
    approvalsWatch

    Tirzepatide on course for European marketing authorization

    medwireNews : The EMA has recommended European use of the first-in-class, dual-action medication tirzepatide  for glucose lowering in people with type 2 diabetes.

  3. 05-06-2022 | ADA 2022 | News | Article

    Renal benefits of tirzepatide revealed

    Tirzepatide may have a renoprotective effect in people with type 2 diabetes and high vascular risk, shows a prespecified analysis of SURPASS-4.

  4. 04-08-2022 | Tirzepatide | News | Article

    SURPASS J trials support tirzepatide use in Japanese people with type 2 diabetes

    Tirzepatide is a promising treatment option for Japanese people with type 2 diabetes when used as monotherapy or added to antihyperglycemic agents, show the SURPASS J-mono and SURPASS J-combo trials.

  5. 16-05-2022 | Tirzepatide | News | Article
    approvalsWatch

    Tirzepatide gets nod from US FDA

    medwireNews : The FDA has approved the first-in-class, dual-action medication tirzepatide  for glucose lowering in people with type 2 diabetes.

  6. 28-04-2022 | Tirzepatide | News | Article

    Mechanisms underlying tirzepatide efficacy revealed

    Tirzepatide improves glucose control more than semaglutide in people with type 2 diabetes by improving beta-cell function as well as boosting insulin sensitivity and reducing glucagon secretion, shows a randomized trial.

  7. 04-06-2022 | ADA 2022 | News | Article

    ​​​​​​​SURMOUNT-1 places tirzepatide weight loss efficacy within surgical range

    A weekly injection of tirzepatide results in a substantial bodyweight reduction over and above that achieved with lifestyle intervention in people with obesity, show the SURMOUNT-1 findings.

  8. 27-04-2022 | Tirzepatide | News | Article

    Tirzepatide reduces liver fat, improves time in range

    The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.

  9. 24-02-2022 | Tirzepatide | News | Article

    Meta-analysis backs tirzepatide CV safety

    A meta-analysis of individual patient data from the SURPASS clinical trial program suggests that tirzepatide has at least a neutral cardiovascular safety profile.

  10. play
    22-10-2021 | Tirzepatide | Video

    SURPASS-4: Tirzepatide as an alternative to insulin glargine in type 2 diabetes

    Stefano Del Prato discusses the advantages of tirzepatide over insulin glargine for people with type 2 diabetes, and how the SURPASS-4 findings fit with those of the rest of the clinical trial program (7:42).

  11. 19-10-2021 | Tirzepatide | News | Article

    Tirzepatide preferable to glargine when OADs fail in SURPASS-4

    Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet .

  12. play
    27-06-2021 | ADA 2021 | Conference coverage | Video

    SURPASS-3: Tirzepatide versus insulin degludec in type 2 diabetes

    Francesco Giorgino discusses the advantages of tirzepatide over insulin degludec revealed in the SURPASS-3 findings for people requiring an injectable therapy for type 2 diabetes.

  13. play
    29-06-2021 | ADA 2021 | Conference coverage | Video

    The SURPASS trials so far: Tirzepatide, semaglutide, and type 2 diabetes

    John Wilding gives an overview of the SURPASS findings to date, and discusses their importance and how tirzepatide may be used in the clinic.

  14. play
    29-06-2021 | ADA 2021 | Conference coverage | Video

    SURPASS-5: Tirzepatide in people with insulin-dependent type 2 diabetes

    Michelle Welch discusses the positive glycemic and weight loss findings for tirzepatide versus placebo in people with insulin-dependent type 2 diabetes in SURPASS-5.

  15. play
    28-06-2021 | ADA 2021 | Conference coverage | Video

    SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes

    Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide.

  16. 26-06-2021 | ADA 2021 | News | Article

    Tirzepatide has efficacy edge over semaglutide in SURPASS-2

    People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.

  17. 26-06-2021 | ADA 2021 | News | Article

    SURPASS-1: Tirzepatide has ‘potent’ glucose-lowering and weight loss efficacy

    The dual GIP and GLP-1 receptor agonist tirzepatide has “potent glucose-lowering effects towards near-normal ranges,” and also induces significant weight loss in people with type 2 diabetes, say the SURPASS-1 investigators.

  18. 26-06-2021 | ADA 2021 | News | Article

    SURPASS-3: Tirzepatide proves better option than degludec for type 2 diabetes

    The SURPASS-3 findings show that people with type 2 diabetes can obtain better glycemic control with tirzepatide than insulin degludec, while losing rather than gaining weight.

  19. 27-06-2021 | ADA 2021 | News | Article

    SURPASS-5: Glycemic, weight benefits of tirzepatide in insulin-dependent type 2 diabetes

    People with insulin-dependent type 2 diabetes significantly improve their glycemic control, lose weight, and require less insulin if they also have a weekly injection of tirzepatide, show the SURPASS-5 findings.

  20. 14-10-2020 | Type 2 diabetes | Editorial | Article

    Tirzepatide: A new challenger for type 2 diabetes management?

    What does the future hold for the novel agent tirzepatide, a GIP/GLP-1 co-agonist? John Wilding examines what we know so far.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.